BioCentury
ARTICLE | Financial News

Atara raises another $150M in latest follow-on

March 1, 2018 4:18 PM UTC

Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million through the sale of 4.3 million shares at $35 in a follow-on underwritten by J.P. Morgan, Cowen, Canaccord Genuity and Mizuho. The price is an 18% discount to Atara's close of $42.55 on Tuesday, when it proposed the offering after market hours. Atara slipped $4.02 to $38.53 on Wednesday, and shed another $1.33 to $37.20 on Thursday.

Atara is conducting two Phase III trials of tabelecleucel (formerly ATA129) to treat Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (EBV-PTLD). Data from the first study are due in 1H19. The company also hopes to submit an MAA to EMA in 1H19 for the allogeneic therapy consisting of EBV-specific cytotoxic T lymphocytes...

BCIQ Company Profiles

Atara Biotherapeutics Inc.